Loerop James 4

What Happened

• James Loerop, Chief Business Officer of Aclaris Therapeutics, was granted two restricted stock unit (RSU) awards on February 2, 2026: 97,700 RSUs and 341,900 RSUs, a total of 439,600 RSUs. The awards are recorded as derivative acquisitions with a grant price of $0 (no cash paid at grant). These are grants (awards), not purchases or sales.

Key Details

• Transaction date: February 2, 2026; grant price reported $0.00 (derivative award).
• Total RSUs granted: 97,700 + 341,900 = 439,600 RSUs.
• Shares owned after transaction: not specified in the provided filing.
• Vesting (per footnotes): each RSU is a contingent right to one share (F1). The RSUs vest in four equal annual installments on the first, second, third and fourth anniversaries of Feb 2, 2026, subject to continuous service (F2).
• Footnote F3 references a standard 4-year option vesting schedule (25% on first anniversary) and appears to describe option terms rather than these RSUs.
• Filing: Form 4 was filed on Feb 6, 2026 for the Feb 2, 2026 grant (filed 4 days after the transaction). Form 4s are typically due within two business days, so this filing appears later than the standard deadline.

Context

• RSUs are contingent awards that convert into shares upon vesting; no shares were provided immediately and no cash was exchanged at grant. Tax withholding and conversion to actual shares occur when RSUs vest. Grants are routine for employee compensation and do not by themselves indicate buying or selling sentiment.